Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,treasuryStock,otherStockholderEquity,shortTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,preMarketChange,preMarketChangePercent,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,INFI,52046000.0,88647200,,,-11629000,,-11629000,3566000,-8016000,-11582000,-11582000,,-45000,,,,0,467000,12049000,8483000,-47000,,-11629000,-11629000,829907000.0,60352000.0,52046000.0,895000.0,112398000.0,89000.0,347000.0,-777950000.0,49581000.0,166000.0,106756000.0,9458000.0,2927000.0,109305000.0,1205000.0,,,,5500000.0,-1646000.0,5500000.0,86133000.0,-665000.0,86133000.0,78163000.0,-13470000.0,119000.0,351000.0,,99847000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,3.59,1630526402,0.049999952,3.58,3.69,3.495,1688695,"Infinity Pharmaceuticals, Inc.",NMS,PRE,0.16230285,0,False,False,1630570291,3.69,1.412428,3.495 - 3.69,3.54,0.0,0.0,418,9,finmb_1208927,NasdaqGS,"Infinity Pharmaceuticals, Inc.",USD,7381151,2324314,2.6499999,2.8191488,0.94 - 5.98,-2.39,-0.39966556,0.94,5.98,1620921900,1636369140,1636718400,-0.64,-0.6,4,0.10000014,2.7855194,-0.55,-6.527272,0.587,2.8462858,0.7437141,0.26129285,3.0886958,0.50130415,318243456,-5.983333,6.115843,15,America/New_York,EDT,-14400000,2.29,,,5.98,0.94,2.8463,3.0887,7.38M,2.32M,88.65M,,71.76M,2.17%,55.96%,3.9M,2.71,4.49%,4.40%,1.93M,,,,,,0.00%,,,1:4,"Sep 12, 2006","Dec 30, 2020","Mar 30, 2021",0.00%,"-2,251.36%",-29.19%,-165.62%,1.76M,0.03,9.10%,-26.08M,-39.1M,-41.23M,-0.6400,,106.76M,1.2,1.81M,3.48,11.56,0.59,-37.43M,-22.86M,Value,02138,Healthcare,23,"Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 453 1000,MA,1609372800,United States,http://www.infi.com,86400,1100 Massachusetts Avenue,617 453 1001,Biotechnology,Floor 4
t-1,INFI,-22989000.0,88647200,,,-10599000,,-10599000,3227000,-7006000,-10233000,-10233000,,-643000,,,,0,436000,10669000,7442000,-366000,,-10599000,-10599000,743269000.0,62308000.0,-22989000.0,848000.0,39319000.0,64000.0,384000.0,-766321000.0,49825000.0,170000.0,28593000.0,11047000.0,3129000.0,36020000.0,2982000.0,-1000.0,-1000.0,5515000.0,17218000.0,1214000.0,17219000.0,1356000.0,201000.0,1356000.0,10065000.0,-8510000.0,119000.0,555000.0,1000.0,24973000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,3.59,1630526402,0.049999952,3.58,3.69,3.495,1688695,"Infinity Pharmaceuticals, Inc.",NMS,PRE,0.16230285,0,False,False,1630570291,3.69,1.412428,3.495 - 3.69,3.54,0.0,0.0,418,9,finmb_1208927,NasdaqGS,"Infinity Pharmaceuticals, Inc.",USD,7381151,2324314,2.6499999,2.8191488,0.94 - 5.98,-2.39,-0.39966556,0.94,5.98,1620921900,1636369140,1636718400,-0.64,-0.6,4,0.10000014,2.7855194,-0.55,-6.527272,0.587,2.8462858,0.7437141,0.26129285,3.0886958,0.50130415,318243456,-5.983333,6.115843,15,America/New_York,EDT,-14400000,2.29,,,5.98,0.94,2.8463,3.0887,7.38M,2.32M,88.65M,,71.76M,2.17%,55.96%,3.9M,2.71,4.49%,4.40%,1.93M,,,,,,0.00%,,,1:4,"Sep 12, 2006","Dec 30, 2020","Mar 30, 2021",0.00%,"-2,251.36%",-29.19%,-165.62%,1.76M,0.03,9.10%,-26.08M,-39.1M,-41.23M,-0.6400,,106.76M,1.2,1.81M,3.48,11.56,0.59,-37.43M,-22.86M,Value,02138,Healthcare,23,"Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 453 1000,MA,1609372800,United States,http://www.infi.com,86400,1100 Massachusetts Avenue,617 453 1001,Biotechnology,Floor 4
t-2,INFI,-14127000.0,88647200,,,-9534000,,-9534000,2930000,-5915000,-8845000,-8845000,,-626000,,,,0,496000,9341000,6411000,-689000,,-9534000,-9534000,741522000.0,61092000.0,-14127000.0,821000.0,46965000.0,63000.0,423000.0,-755722000.0,49698000.0,174000.0,18528000.0,9834000.0,3316000.0,43475000.0,1132000.0,10000.0,10000.0,22757000.0,-8993000.0,574000.0,-8993000.0,6483000.0,129000.0,6483000.0,-10393000.0,-7883000.0,122000.0,826000.0,1000.0,33641000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,3.59,1630526402,0.049999952,3.58,3.69,3.495,1688695,"Infinity Pharmaceuticals, Inc.",NMS,PRE,0.16230285,0,False,False,1630570291,3.69,1.412428,3.495 - 3.69,3.54,0.0,0.0,418,9,finmb_1208927,NasdaqGS,"Infinity Pharmaceuticals, Inc.",USD,7381151,2324314,2.6499999,2.8191488,0.94 - 5.98,-2.39,-0.39966556,0.94,5.98,1620921900,1636369140,1636718400,-0.64,-0.6,4,0.10000014,2.7855194,-0.55,-6.527272,0.587,2.8462858,0.7437141,0.26129285,3.0886958,0.50130415,318243456,-5.983333,6.115843,15,America/New_York,EDT,-14400000,2.29,,,5.98,0.94,2.8463,3.0887,7.38M,2.32M,88.65M,,71.76M,2.17%,55.96%,3.9M,2.71,4.49%,4.40%,1.93M,,,,,,0.00%,,,1:4,"Sep 12, 2006","Dec 30, 2020","Mar 30, 2021",0.00%,"-2,251.36%",-29.19%,-165.62%,1.76M,0.03,9.10%,-26.08M,-39.1M,-41.23M,-0.6400,,106.76M,1.2,1.81M,3.48,11.56,0.59,-37.43M,-22.86M,Value,02138,Healthcare,23,"Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 453 1000,MA,1609372800,United States,http://www.infi.com,86400,1100 Massachusetts Avenue,617 453 1001,Biotechnology,Floor 4
t-3,INFI,-11384000.0,88647200,,,-9473000,,-9473000,2937000,-5982000,-8919000,-8919000,,-604000,,,,0,360000,9279000,6342000,-554000,,-9473000,-9473000,734701000.0,60040000.0,-11384000.0,565000.0,48656000.0,57000.0,219000.0,-746188000.0,49475000.0,328000.0,28921000.0,8877000.0,3534000.0,44794000.0,1289000.0,46000.0,46000.0,13809000.0,6001000.0,369000.0,5975000.0,30000.0,591000.0,30000.0,-1564000.0,-7569000.0,122000.0,822000.0,-26000.0,35917000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,3.59,1630526402,0.049999952,3.58,3.69,3.495,1688695,"Infinity Pharmaceuticals, Inc.",NMS,PRE,0.16230285,0,False,False,1630570291,3.69,1.412428,3.495 - 3.69,3.54,0.0,0.0,418,9,finmb_1208927,NasdaqGS,"Infinity Pharmaceuticals, Inc.",USD,7381151,2324314,2.6499999,2.8191488,0.94 - 5.98,-2.39,-0.39966556,0.94,5.98,1620921900,1636369140,1636718400,-0.64,-0.6,4,0.10000014,2.7855194,-0.55,-6.527272,0.587,2.8462858,0.7437141,0.26129285,3.0886958,0.50130415,318243456,-5.983333,6.115843,15,America/New_York,EDT,-14400000,2.29,,,5.98,0.94,2.8463,3.0887,7.38M,2.32M,88.65M,,71.76M,2.17%,55.96%,3.9M,2.71,4.49%,4.40%,1.93M,,,,,,0.00%,,,1:4,"Sep 12, 2006","Dec 30, 2020","Mar 30, 2021",0.00%,"-2,251.36%",-29.19%,-165.62%,1.76M,0.03,9.10%,-26.08M,-39.1M,-41.23M,-0.6400,,106.76M,1.2,1.81M,3.48,11.56,0.59,-37.43M,-22.86M,Value,02138,Healthcare,23,"Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 453 1000,MA,1609372800,United States,http://www.infi.com,86400,1100 Massachusetts Avenue,617 453 1001,Biotechnology,Floor 4
